Sanofi Pasteur helps you guard against getting sick in the first place. The company is the US unit of Sanofi Pasteur SA, the vaccines division of French drugmaker Sanofi. It researches, makes, and markets about 20 vaccines that protect against such bacterial and viral diseases as diphtheria, hepatitis, polio, and meningitis. Some of Sanofi Pasteur's top sellers are Fluzone influenza vaccines, childhood combination vaccines, and adult booster shots. It also makes travelers' vaccines that keep globetrotters safe from typhoid, cholera, yellow fever, and the like.
While it might seem a bit dark to be betting on a worst-case scenario, Sanofi Pasteur is the largest flu vaccine maker in the world and it's working on improving flu vaccines to prepare for a potential influenza pandemic.
On the global front, parent Sanofi Pasteur SA operates in about 150 countries, and more than 500 million people around the world receive its vaccines each year. The unit provides a total of more than 1 billion vaccine doses annually.
The company is headquartered in Swiftwater, Pennsylvania, and operates in Cambridge and Canton, Massachusetts; Orlando, Florida; and Rockville, Maryland.
Sales and Marketing
Sanofi Pasteur sells and distributes its products through multiple channels, including the private sector (physicians, pharmacies, hospitals, private companies and distributors) and the public sector (governmental organizations and non-government organizations).
The international vaccines organization includes Sanofi Pasteur MSD, which markets products in Europe including Merck's cervical cancer vaccine Gardasil.
Sanofi Pasteur SA, of which Sanofi Pasteur is a part, provides 12% of its Sanofi's total revenues.
The company benefits from demands for traditional and seasonal vaccines. Sanofi Pasteur supplies about 40% of seasonal vaccines in the US.
In addition to its influenza research, Sanofi Pasteur has about 20 vaccines in its R&D pipeline, including improvements to its existing vaccines, as well as new vaccines for some forms of cancer, dengue fever, HIV, and rabies. About a dozen are in development or have been submitted for approval. In 2013 the FDA approved the supplemental biologics license application for the licensing of its four-strain influenza vaccine Fluzone Quadrivalent. The following year, similar approval was given to the Fluzone Intradermal Quadrivalent vaccine.